Charles Schwab Investment Management Inc. Acquires 90,557 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE)

Charles Schwab Investment Management Inc. lifted its position in Gyre Therapeutics, Inc. (NASDAQ:GYRE) by 392.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 113,648 shares of the company’s stock after buying an additional 90,557 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Gyre Therapeutics were worth $1,425,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the company. WINTON GROUP Ltd acquired a new position in shares of Gyre Therapeutics in the second quarter valued at $220,000. Bank of New York Mellon Corp acquired a new position in Gyre Therapeutics in the second quarter valued at about $218,000. Renaissance Technologies LLC bought a new position in Gyre Therapeutics in the second quarter valued at approximately $166,000. Finally, Rhumbline Advisers bought a new stake in shares of Gyre Therapeutics during the 2nd quarter worth $123,000. 23.99% of the stock is currently owned by institutional investors and hedge funds.

Gyre Therapeutics Stock Performance

Shares of Gyre Therapeutics stock opened at $9.99 on Tuesday. Gyre Therapeutics, Inc. has a fifty-two week low of $8.26 and a fifty-two week high of $30.40. The company’s 50 day moving average price is $13.01 and its two-hundred day moving average price is $12.61.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.